{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:41:03Z","timestamp":1794271263384,"version":"4.9.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T00:00:00Z","timestamp":1503964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T00:00:00Z","timestamp":1503964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Serelaxin, a recombinant form of the naturally occurring peptide hormone relaxin-2, is a pleiotropic vasodilating hormone that has been studied in patients with acute heart failure. In this study, the effects of serelaxin on cardiac and renal function, fibrosis, inflammation and lipid accumulation were studied in DOCA-salt treated rats. Uninephrectomized rats were assigned to two groups: controls provided with normal drinking water and DOCA provided with DOCA pellets and sodium chloride drinking water. After 4 weeks, the DOCA-salt rats were randomly selected and implanted with osmotic minipumps delivering vehicle or serelaxin for another 4 weeks. Treatment with serelaxin prevented cardiac and renal dysfunction in DOCA-salt rats. Serelaxin prevented cardiac and renal fibrosis, as determined by Picrosirius Red staining and Second Harmonic Generation (SHG) Microscopy. Treatment of DOCA-salt rats with serelaxin decreased renal inflammation, including the expression of TGF-\u03b2, NF\u03baB, MCP-1, IL-<jats:bold>1<\/jats:bold>, IL-<jats:bold>6<\/jats:bold>, ICAM-1, VCAM-1 and CD68 macrophages. Serelaxin also decreased lipid accumulation in kidney in part by decreasing SREBP-1c, SREBP-2, ChREBP, FATP1, HMGCoAR, and LDL receptor, and increasing Acox1 and ABCA1. In summary, serelaxin reversed DOCA-salt induced cardiac and renal dysfunction.<\/jats:p>","DOI":"10.1038\/s41598-017-09470-0","type":"journal-article","created":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T10:19:40Z","timestamp":1503483580000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Serelaxin improves cardiac and renal function in DOCA-salt hypertensive rats"],"prefix":"10.1038","volume":"7","author":[{"given":"Dong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhuan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komuraiah","family":"Myakala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Orlicky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgenia","family":"Dobrinskikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Levi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,29]]},"reference":[{"key":"9470_CR1","unstructured":"Ojo, A. Addressing the global burden of chronic kidney disease through clinical and translational research. Trans Am Clin Climatol Assoc \n                           125, 229\u2013243; discussion 243\u2013226 (2014)."},{"key":"9470_CR2","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.2215\/CJN.04660511","volume":"6","author":"SC Chen","year":"2011","unstructured":"Chen, S. C. et al. Echocardiographic parameters are independently associated with rate of renal function decline and progression to dialysis in patients with chronic kidney disease. Clin J Am Soc Nephrol \n                           6, 2750\u20132758, doi:10.2215\/CJN.04660511 (2011).","journal-title":"Clin J Am Soc Nephrol"},{"key":"9470_CR3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.pharmthera.2006.03.004","volume":"112","author":"T Dschietzig","year":"2006","unstructured":"Dschietzig, T., Bartsch, C., Baumann, G. & Stangl, K. Relaxin-a pleiotropic hormone and its emerging role for experimental and clinical therapeutics. Pharmacol Ther \n                           112, 38\u201356, doi:10.1016\/j.pharmthera.2006.03.004 (2006).","journal-title":"Pharmacol Ther"},{"key":"9470_CR4","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/j.1749-6632.2008.03800.x","volume":"1160","author":"LT Goldsmith","year":"2009","unstructured":"Goldsmith, L. T. & Weiss, G. Relaxin in human pregnancy. Ann N Y Acad Sci \n                           1160, 130\u2013135, doi:10.1111\/j.1749-6632.2008.03800.x (2009).","journal-title":"Ann N Y Acad Sci"},{"key":"9470_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/978-0-387-74672-2_5","volume":"612","author":"AI Agoulnik","year":"2007","unstructured":"Agoulnik, A. I. Relaxin and related peptides in male reproduction. Adv Exp Med Biol \n                           612, 49\u201364, doi:10.1007\/978-0-387-74672-2_5 (2007).","journal-title":"Adv Exp Med Biol"},{"key":"9470_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2148-5-14","volume":"5","author":"TN Wilkinson","year":"2005","unstructured":"Wilkinson, T. N., Speed, T. P., Tregear, G. W. & Bathgate, R. A. Evolution of the relaxin-like peptide family. BMC Evol Biol \n                           5, 14, doi:10.1186\/1471-2148-5-14 (2005).","journal-title":"BMC Evol Biol"},{"key":"9470_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(12)61855-8","volume":"381","author":"JR Teerlink","year":"2013","unstructured":"Teerlink, J. R. et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet \n                           381, 29\u201339, doi:10.1016\/S0140-6736(12)61855-8 (2013).","journal-title":"Lancet"},{"key":"9470_CR8","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1096\/fj.08-120857","volume":"23","author":"I Mookerjee","year":"2009","unstructured":"Mookerjee, I. et al. Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2. FASEB J \n                           23, 1219\u20131229, doi:10.1096\/fj.08-120857 (2009).","journal-title":"FASEB J"},{"key":"9470_CR9","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1210\/en.2004-1602","volume":"146","author":"LJ Kerchner","year":"2005","unstructured":"Kerchner, L. J. et al. Evidence against the hypothesis that endothelial endothelin B receptor expression is regulated by relaxin and pregnancy. Endocrinology \n                           146, 2791\u20132797, doi:10.1210\/en.2004-1602 (2005).","journal-title":"Endocrinology"},{"key":"9470_CR10","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1161\/HYPERTENSIONAHA.114.03594","volume":"64","author":"CS Samuel","year":"2014","unstructured":"Samuel, C. S. et al. Serelaxin is a more efficacious antifibrotic than enalapril in an experimental model of heart disease. Hypertension \n                           64, 315\u2013322, doi:10.1161\/HYPERTENSIONAHA.114.03594 (2014).","journal-title":"Hypertension"},{"key":"9470_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/srep39604","volume":"7","author":"HH Ng","year":"2017","unstructured":"Ng, H. H. et al. Serelaxin treatment reverses vascular dysfunction and left ventricular hypertrophy in a mouse model of Type 1 diabetes. Sci Rep \n                           7, 39604, doi:10.1038\/srep39604 (2017).","journal-title":"Sci Rep"},{"key":"9470_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/ehjcvp\/pvv046","volume":"2","author":"J Diez","year":"2016","unstructured":"Diez, J. & Ruilope, L. M. Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection. Eur Heart J Cardiovasc Pharmacother \n                           2, 119\u2013130, doi:10.1093\/ehjcvp\/pvv046 (2016).","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"9470_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvw246","author":"J Valle Raleigh","year":"2017","unstructured":"Valle Raleigh, J. et al. Reperfusion therapy with recombinant human relaxin-2 (Serelaxin) attenuates myocardial infarct size and NLRP3 inflammasome following ischemia\/reperfusion injury via eNOS-dependent mechanism. Cardiovasc Res., doi:10.1093\/cvr\/cvw246 (2017).","journal-title":"Cardiovasc Res."},{"key":"9470_CR14","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1159\/000464125","volume":"41","author":"J Cai","year":"2017","unstructured":"Cai, J. et al. Anti-Fibrosis Effect of Relaxin and Spironolactone Combined on Isoprenaline-Induced Myocardial Fibrosis in Rats via Inhibition of Endothelial-Mesenchymal Transition. Cell Physiol Biochem \n                           41, 1167\u20131178, doi:10.1159\/000464125 (2017).","journal-title":"Cell Physiol Biochem"},{"key":"9470_CR15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11897-010-0010-z","volume":"7","author":"SL Teichman","year":"2010","unstructured":"Teichman, S. L., Unemori, E., Teerlink, J. R., Cotter, G. & Metra, M. Relaxin: review of biology and potential role in treating heart failure. Curr Heart Fail Rep \n                           7, 75\u201382, doi:10.1007\/s11897-010-0010-z (2010).","journal-title":"Curr Heart Fail Rep"},{"key":"9470_CR16","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/eurheartj\/eht459","volume":"35","author":"P Ponikowski","year":"2014","unstructured":"Ponikowski, P. et al. A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. Eur Heart J \n                           35, 431\u2013441, doi:10.1093\/eurheartj\/eht459 (2014).","journal-title":"Eur Heart J"},{"key":"9470_CR17","doi-asserted-by":"publisher","first-page":"R322","DOI":"10.1152\/ajpregu.00509.2004","volume":"288","author":"AH Bogzil","year":"2005","unstructured":"Bogzil, A. H., Eardley, R. & Ashton, N. Relaxin-induced changes in renal sodium excretion in the anesthetized male rat. Am J Physiol Regul Integr Comp Physiol \n                           288, R322\u2013328, doi:10.1152\/ajpregu.00509.2004 (2005).","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"9470_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002248","volume":"14","author":"VK Snowdon","year":"2017","unstructured":"Snowdon, V. K. et al. Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial. PLoS Med \n                           14, e1002248, doi:10.1371\/journal.pmed.1002248 (2017).","journal-title":"PLoS Med"},{"key":"9470_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-017-0731-4","volume":"19","author":"T Basting","year":"2017","unstructured":"Basting, T. & Lazartigues, E. DOCA-Salt Hypertension: an Update. Curr Hypertens Rep \n                           19, 32, doi:10.1007\/s11906-017-0731-4 (2017).","journal-title":"Curr Hypertens Rep"},{"key":"9470_CR20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2174\/157340310793566109","volume":"6","author":"A Iyer","year":"2010","unstructured":"Iyer, A., Chan, V. & Brown, L. The DOCA-Salt Hypertensive Rat as a Model of Cardiovascular Oxidative and Inflammatory Stress. Curr Cardiol Rev \n                           6, 291\u2013297, doi:10.2174\/157340310793566109 (2010).","journal-title":"Curr Cardiol Rev"},{"key":"9470_CR21","first-page":"1893","volume":"74","author":"J Doust","year":"2006","unstructured":"Doust, J., Lehman, R. & Glasziou, P. The role of BNP testing in heart failure. Am Fam Physician \n                           74, 1893\u20131898 (2006).","journal-title":"Am Fam Physician"},{"key":"9470_CR22","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1073\/pnas.81.9.2626","volume":"81","author":"V Mahdavi","year":"1984","unstructured":"Mahdavi, V., Chambers, A. P. & Nadal-Ginard, B. Cardiac alpha- and beta-myosin heavy chain genes are organized in tandem. Proc Natl Acad Sci USA \n                           81, 2626\u20132630 (1984).","journal-title":"Proc Natl Acad Sci USA"},{"key":"9470_CR23","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1152\/japplphysiol.00224.2015","volume":"119","author":"P Vutthasathien","year":"2015","unstructured":"Vutthasathien, P. & Wattanapermpool, J. Regular exercise improves cardiac contractile activation by modulating MHC isoforms and SERCA activity in orchidectomized rats. J Appl Physiol (1985) \n                           119, 831\u2013839, doi:10.1152\/japplphysiol.00224.2015 (2015).","journal-title":"J Appl Physiol (1985)"},{"key":"9470_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2016.00106","volume":"7","author":"BL de Melo","year":"2016","unstructured":"de Melo, B. L. et al. Exercise Training Attenuates Right Ventricular Remodeling in Rats with Pulmonary Arterial Stenosis. Front Physiol \n                           7, 541, doi:10.3389\/fphys.2016.00541 (2016).","journal-title":"Front Physiol"},{"key":"9470_CR25","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.kint.2016.06.030","volume":"90","author":"S Ranjit","year":"2016","unstructured":"Ranjit, S. et al. Label-free fluorescence lifetime and second harmonic generation imaging microscopy improves quantification of experimental renal fibrosis. Kidney Int \n                           90, 1123\u20131128, doi:10.1016\/j.kint.2016.06.030 (2016).","journal-title":"Kidney Int"},{"key":"9470_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/srep13378","volume":"5","author":"S Ranjit","year":"2015","unstructured":"Ranjit, S. et al. Imaging Fibrosis and Separating Collagens using Second Harmonic Generation and Phasor Approach to Fluorescence Lifetime Imaging. Sci Rep \n                           5, 13378, doi:10.1038\/srep13378 (2015).","journal-title":"Sci Rep"},{"key":"9470_CR27","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1046\/j.1523-1755.2002.00433.x","volume":"62","author":"WK Han","year":"2002","unstructured":"Han, W. K., Bailly, V., Abichandani, R., Thadhani, R. & Bonventre, J. V. Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int \n                           62, 237\u2013244, doi:10.1046\/j.1523-1755.2002.00433.x (2002).","journal-title":"Kidney Int"},{"key":"9470_CR28","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrneph.2016.75","volume":"12","author":"VD D\u2019Agati","year":"2016","unstructured":"D\u2019Agati, V. D. et al. Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis. Nat Rev Nephrol \n                           12, 453\u2013471, doi:10.1038\/nrneph.2016.75 (2016).","journal-title":"Nat Rev Nephrol"},{"key":"9470_CR29","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.2337\/db05-0603","volume":"55","author":"G Proctor","year":"2006","unstructured":"Proctor, G. et al. Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in Akita and OVE26 mice with type 1 diabetes. Diabetes \n                           55, 2502\u20132509, doi:10.2337\/db05-0603 (2006).","journal-title":"Diabetes"},{"key":"9470_CR30","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.2337\/diabetes.54.8.2328","volume":"54","author":"Z Wang","year":"2005","unstructured":"Wang, Z. et al. Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb\/db mice with type 2 diabetes. Diabetes \n                           54, 2328\u20132335 (2005).","journal-title":"Diabetes"},{"key":"9470_CR31","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s40256-013-0041-4","volume":"13","author":"A Olyaei","year":"2013","unstructured":"Olyaei, A. et al. HMG-CoA reductase inhibitors in chronic kidney disease. Am J Cardiovasc Drugs \n                           13, 385\u2013398, doi:10.1007\/s40256-013-0041-4 (2013).","journal-title":"Am J Cardiovasc Drugs"},{"key":"9470_CR32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0021-9150(01)00762-6","volume":"164","author":"AR Miserez","year":"2002","unstructured":"Miserez, A. R. et al. Sterol-regulatory element-binding protein (SREBP)-2 contributes to polygenic hypercholesterolaemia. Atherosclerosis \n                           164, 15\u201326 (2002).","journal-title":"Atherosclerosis"},{"key":"9470_CR33","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S0733-8651(02)00004-8","volume":"20","author":"GA Mensah","year":"2002","unstructured":"Mensah, G. A., Croft, J. B. & Giles, W. H. The heart, kidney, and brain as target organs in hypertension. Cardiol Clin \n                           20, 225\u2013247 (2002).","journal-title":"Cardiol Clin"},{"key":"9470_CR34","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1096\/fj.04-3664fje","volume":"19","author":"AM Perna","year":"2005","unstructured":"Perna, A. M. et al. Novel drug development opportunity for relaxin in acute myocardial infarction: evidences from a swine model. FASEB J \n                           19, 1525\u20131527, doi:10.1096\/fj.04-3664fje (2005).","journal-title":"FASEB J"},{"key":"9470_CR35","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1172\/JCI5630","volume":"103","author":"LA Danielson","year":"1999","unstructured":"Danielson, L. A., Sherwood, O. D. & Conrad, K. P. Relaxin is a potent renal vasodilator in conscious rats. J Clin Invest \n                           103, 525\u2013533, doi:10.1172\/JCI5630 (1999).","journal-title":"J Clin Invest"},{"key":"9470_CR36","doi-asserted-by":"publisher","first-page":"F1169","DOI":"10.1152\/ajprenal.00654.2012","volume":"305","author":"T Yoshida","year":"2013","unstructured":"Yoshida, T., Kumagai, H., Kohsaka, T. & Ikegaya, N. Relaxin protects against renal ischemia-reperfusion injury. Am J Physiol Renal Physiol \n                           305, F1169\u20131176, doi:10.1152\/ajprenal.00654.2012 (2013).","journal-title":"Am J Physiol Renal Physiol"},{"key":"9470_CR37","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1681\/ASN.2005121307","volume":"17","author":"LA Danielson","year":"2006","unstructured":"Danielson, L. A., Welford, A. & Harris, A. Relaxin improves renal function and histology in aging Munich Wistar rats. J Am Soc Nephrol \n                           17, 1325\u20131333, doi:10.1681\/ASN.2005121307 (2006).","journal-title":"J Am Soc Nephrol"},{"key":"9470_CR38","doi-asserted-by":"crossref","first-page":"R1298","DOI":"10.1152\/ajpregu.2000.279.4.R1298","volume":"279","author":"LA Danielson","year":"2000","unstructured":"Danielson, L. A., Kercher, L. J. & Conrad, K. P. Impact of gender and endothelin on renal vasodilation and hyperfiltration induced by relaxin in conscious rats. Am J Physiol Regul Integr Comp Physiol \n                           279, R1298\u20131304 (2000).","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"9470_CR39","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1681\/ASN.2005090950","volume":"17","author":"MC Smith","year":"2006","unstructured":"Smith, M. C., Danielson, L. A., Conrad, K. P. & Davison, J. M. Influence of recombinant human relaxin on renal hemodynamics in healthy volunteers. J Am Soc Nephrol \n                           17, 3192\u20133197, doi:10.1681\/ASN.2005090950 (2006).","journal-title":"J Am Soc Nephrol"},{"key":"9470_CR40","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10741-007-9017-2","volume":"12","author":"SM Hollenberg","year":"2007","unstructured":"Hollenberg, S. M. Vasodilators in acute heart failure. Heart Fail Rev \n                           12, 143\u2013147, doi:10.1007\/s10741-007-9017-2 (2007).","journal-title":"Heart Fail Rev"},{"key":"9470_CR41","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1161\/01.HYP.0000184230.52059.33","volume":"46","author":"DO Debrah","year":"2005","unstructured":"Debrah, D. O., Conrad, K. P., Jeyabalan, A., Danielson, L. A. & Shroff, S. G. Relaxin increases cardiac output and reduces systemic arterial load in hypertensive rats. Hypertension \n                           46, 745\u2013750, doi:10.1161\/01.HYP.0000184230.52059.33 (2005).","journal-title":"Hypertension"},{"key":"9470_CR42","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1152\/japplphysiol.00845.2010","volume":"111","author":"DO Debrah","year":"2011","unstructured":"Debrah, D. O. et al. Relaxin regulates vascular wall remodeling and passive mechanical properties in mice. J Appl Physiol (1985) \n                           111, 260\u2013271, doi:10.1152\/japplphysiol.00845.2010 (2011).","journal-title":"J Appl Physiol (1985)"},{"key":"9470_CR43","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/157016112798829760","volume":"10","author":"D Tousoulis","year":"2012","unstructured":"Tousoulis, D., Kampoli, A. M., Tentolouris, C., Papageorgiou, N. & Stefanadis, C. The role of nitric oxide on endothelial function. Curr Vasc Pharmacol \n                           10, 4\u201318 (2012).","journal-title":"Curr Vasc Pharmacol"},{"key":"9470_CR44","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1152\/physrev.00001.2012","volume":"93","author":"RA Bathgate","year":"2013","unstructured":"Bathgate, R. A. et al. Relaxin family peptides and their receptors. Physiol Rev \n                           93, 405\u2013480, doi:10.1152\/physrev.00001.2012 (2013).","journal-title":"Physiol Rev"},{"key":"9470_CR45","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s10741-008-9129-3","volume":"14","author":"SL Teichman","year":"2009","unstructured":"Teichman, S. L. et al. Relaxin, a pleiotropic vasodilator for the treatment of heart failure. Heart Fail Rev \n                           14, 321\u2013329, doi:10.1007\/s10741-008-9129-3 (2009).","journal-title":"Heart Fail Rev"},{"key":"9470_CR46","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1111\/j.1755-5922.2010.00228.x","volume":"30","author":"AJ Edgley","year":"2012","unstructured":"Edgley, A. J., Krum, H. & Kelly, D. J. Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor-beta. Cardiovasc Ther \n                           30, e30\u201340, doi:10.1111\/j.1755-5922.2010.00228.x (2012).","journal-title":"Cardiovasc Ther"},{"key":"9470_CR47","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ejheart.2008.01.007","volume":"10","author":"G Cotter","year":"2008","unstructured":"Cotter, G., Metra, M., Milo-Cotter, O., Dittrich, H. C. & Gheorghiade, M. Fluid overload in acute heart failure\u2013re-distribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail \n                           10, 165\u2013169, doi:10.1016\/j.ejheart.2008.01.007 (2008).","journal-title":"Eur J Heart Fail"},{"key":"9470_CR48","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40256-014-0069-0","volume":"14","author":"J Diez","year":"2014","unstructured":"Diez, J. Serelaxin: a novel therapy for acute heart failure with a range of hemodynamic and non-hemodynamic actions. Am J Cardiovasc Drugs \n                           14, 275\u2013285, doi:10.1007\/s40256-014-0069-0 (2014).","journal-title":"Am J Cardiovasc Drugs"},{"key":"9470_CR49","doi-asserted-by":"publisher","first-page":"41G","DOI":"10.1016\/j.amjcard.2005.07.020","volume":"96","author":"WG Stough","year":"2005","unstructured":"Stough, W. G., O\u2019Connor, C. M. & Gheorghiade, M. Overview of current noninodilator therapies for acute heart failure syndromes. Am J Cardiol \n                           96, 41G\u201346G, doi:10.1016\/j.amjcard.2005.07.020 (2005).","journal-title":"Am J Cardiol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-09470-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-09470-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-09470-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T09:46:29Z","timestamp":1671788789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-09470-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,29]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["9470"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-09470-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,29]]},"assertion":[{"value":"5 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was supported by IIS grant support from Novartis to University of Colorado and Moshe Levi. No other conflicts of interest, financial or otherwise, are declared by the author(s).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"9793"}}